New Delhi, India – 110 016
South Delhi Pharma, New Delhi, India
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.
CALQUENCE is a prescription medicine. CALQUENCE is used to treat mantle cell lymphoma (MCL).
INDICATIONS AND USAGE
CALQUENCE is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
DOSAGE FORMS & STRENGTHS
Capsules: 100 mg
Manufactured By: AstraZeneca
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “CALQUENCE ® (acalabrutinib) capsules” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
Contact Number:
M:+91-9891296838 / P:+91-11- 26532129
Email ID:
info@southdelhipharma.com
Acalabrutinib, sold under the brand name Calquence, is a medication used to treat a type of non-Hodgkin lymphoma known as mantle cell lymphoma. Specifically it is for people who had previously been treated with another therapy. As of 2019, it was unclear whether it improved outcomes.
Acalabrutinib was approved for medical use in the United States in 2017, and in the European Union in November 2020
